By blocking available receptors with trastuzumab or by injecting the non-targeting drug conjugate 99mTc-ADAPTNeg-ABD-mcDM1, a specificity test to investigate if tumor uptake was HER2 mediated, was performed. This evidence concerns the gene ERBB2 and neoplasm.